Study of DM5167 in Patients With Advanced Solid Tumors

DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.

Trial Details

NCT ID
NCT07101601
Phase
PHASE1
Sponsor
DIGMBIO
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • DM5167
Locations (sample)
  • Gyeonggi-do, South Korea|37.58944,126.76917
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Men and women aged 19 years or older as of the date of written informed consent
  • Patients who have at least one measurable lesion according to RECIST version 1.1
  • ECOG performance status ≤ 1
  • Patients with life expectancy ≥ 12 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →